<?xml version='1.0' encoding='utf-8'?>

<rss version="2.0">
  <channel>
    <title>The Federal Register</title>
    <link>http://thefederalregister.com/b.p/agency/Food_and_Drug_Administration/2006-12-07/</link>
    <description>Daily Publications of Meetings and Rules Changes for the Federal Government</description>
    <pubDate>Sun, Nov 23 2008 11:00:00 GMT</pubDate>
    <lastBuildDate>Sun, Nov 23 2008 11:00:00 GMT</lastBuildDate>
    <webMaster>info@thefederalregister.com</webMaster>
    <item>
  <title><![CDATA[  Use of Ozone-Depleting Substances; Removal of Essential Use  Designations]]></title>
  <link>http://thefederalregister.com/d.p/2006-12-07-E6-20797</link>
  <description><![CDATA[ The Food and Drug Administration (FDA) is amending its 
regulation on the use of ozonedepleting substances (ODSs) in 
pressurized containers to remove the essential use designations for 
beclomethasone, dexamethasone, fluticasone, bitolterol, salmeterol, 
ergotamine tartrate, and ipratropium bromide used in oral pressurized 
metereddose inhalers (MDIs). Under the Clean Air Act, FDA, in 
consultation with the Environmental Protection Agency (EPA), is 
required to determine whether an FDAregulated product that releases an 
ODS is essential. None of these products is currently being marketed, 
which provides grounds for removing their essential use designation. We 
are using direct final rulemaking for this action because the agency 
expects that there will be no significant adverse comment on the rule. 
In the proposed rule section in this issue of the Federal Register, we 
are concurrently proposing and soliciting comments on this rule. If [[Page 70871]]<br/>
significant adverse comments are received, we will with<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2006-12-07-E6-20797</guid>
  <pubDate>Thu, Dec 7 2006 11:00:00 GMT</pubDate>
</item>
<item>
  <title><![CDATA[  Color Additive Certification; Increase in Fees for Certification  Services]]></title>
  <link>http://thefederalregister.com/d.p/2006-12-07-E6-20800</link>
  <description><![CDATA[ The Food and Drug Administration (FDA) is amending an interim 
final rule (IFR) that was published in the Federal Register of March 
29, 2005 (70 FR 15755). The IFR amended the color additive regulations 
by increasing the fees for certification services. The IFR was 
published with one typographical error regarding fees for repacks of 
certified color additives and color additive mixtures. FDA also 
inadvertently omitted the color certification fee study referenced in 
the IFR from the docket at the time of publication. This document 
corrects the typographical error in the fees for repacks of certified 
color additives and color additive mixtures, announces the availability 
of the referenced color certification fee study, and provides for 
additional time to submit comments.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2006-12-07-E6-20800</guid>
  <pubDate>Thu, Dec 7 2006 11:00:00 GMT</pubDate>
</item>
<item>
  <title><![CDATA[  Use of Ozone-Depleting Substances; Removal of Essential Use  Designations; Companion Document to Direct Final Rule]]></title>
  <link>http://thefederalregister.com/d.p/2006-12-07-E6-20796</link>
  <description><![CDATA[ The Food and Drug Administration (FDA) is publishing this 
companion proposed rule to the direct final rule, published elsewhere 
in this issue of the Federal Register, that is intended to amend our 
regulation on the use of ozonedepleting substances (ODSs) in 
pressurized containers to remove the essential use designations for 
beclomethasone, dexamethasone, fluticasone, bitolterol, salmeterol, 
ergotamine tartrate, and ipratropium bromide used in oral pressurized 
metereddose inhalers (MDIs). Under the Clean Air Act, FDA, in 
consultation with the Environmental Protection Agency (EPA), is 
required to determine whether an FDAregulated product that releases an 
ODS is essential. None of these products is currently being marketed, 
which provides grounds for removing their essential use designation.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2006-12-07-E6-20796</guid>
  <pubDate>Thu, Dec 7 2006 11:00:00 GMT</pubDate>
</item>
<item>
  <title><![CDATA[  Agency Information Collection Activities; Submission for Office  of Management and Budget Review; Comment Request;]]></title>
  <link>http://thefederalregister.com/d.p/2006-12-07-E6-20704</link>
  <description><![CDATA[  The Food and Drug Administration (FDA) is announcing that a 
proposed collection of information has been submitted to the Office of 
Management and Budget (OMB) for review and clearance under the 
Paperwork Reduction Act of 1995.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2006-12-07-E6-20704</guid>
  <pubDate>Thu, Dec 7 2006 11:00:00 GMT</pubDate>
</item>
<item>
  <title><![CDATA[  Withdrawal of Federal Register Notice ]]></title>
  <link>http://thefederalregister.com/d.p/2006-12-07-E6-20705</link>
  <description><![CDATA[ The Food and Drug Administration (FDA) is announcing the 
withdrawal of a 60day notice that published in the Federal Register of 
October 31, 2006 (71 FR 63765). The document published in error.
<script type="text/javascript">
<!--
google_ad_client = "pub-2051746026283201";
google_ad_width = 728;
google_ad_height = 15;
google_ad_format = "728x15_0ads_al";
//2007-08-22: federalregister-rss
google_ad_channel = "2005962856";
google_color_border = "CC0000";
google_color_bg = "FFFFFF";
google_color_link = "CC0000";
google_color_text = "000000";
google_color_url = "008000";
//-->
</script>
<script type="text/javascript"
  src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
</script>
]]></description>
  <guid>http://thefederalregister.com/d.p/2006-12-07-E6-20705</guid>
  <pubDate>Thu, Dec 7 2006 11:00:00 GMT</pubDate>
</item>
</channel>
</rss>

